

## Other indications for Everolimus

### → *Renal cell cancer, advanced:*

*Oral:* 10 mg once daily, continue treatment until disease progression or unacceptable toxicity.

### → *Renal cell carcinoma, advanced (off-label dose/combination):*

*Oral:* 5 mg once daily (in combination with lenvatinib), continue until disease progression or unacceptable toxicity. <sup>[1] [2] [3]</sup>

### → *Tuberous sclerosis complex-associated partial-onset seizures (dosing based on body surface area):*

*Oral: Initial:* 5 mg/m<sup>2</sup> once daily; continue until disease progression or unacceptable toxicity.

### → *Tuberous sclerosis complex-associated renal angiomyolipoma:*

*Oral:* 10 mg once daily, continue treatment until disease progression or unacceptable toxicity.

### → *Tuberous sclerosis complex-associated subependymal giant cell astrocytoma (SEGA; dosing based on BSA):*

*Oral: Initial:* 4.5 mg/m<sup>2</sup> once daily; continue until disease progression or unacceptable toxicity.

---

[ 1 ] - Motzer RJ, Escudier B, Oudard S, et al, "Efficacy of Everolimus in Advanced Renal Cell Carcinoma: A Double-Blind, Randomised, Placebo-Controlled Phase III Trial," Lancet, 2008, 372(9637):449-56. [\[PubMed 18653228\]](#)

[2]- Motzer RJ, Escudier B, Oudard S, et al, "Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma: Final Results and Analysis of Prognostic Factors," Cancer, 2010, 116(18):4256-65. [\[PubMed 20549832\]](#)

[3]- Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473-1482. [\[PubMed 26482279\]](#)

